Nektar Therapeutics (NKTR) News
Nektar Therapeutics (NKTR)
Today's Latest Price: $16.53 USD
Updated Oct 1 11:48am
Add NKTR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
Filter NKTR News Items
NKTR News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NKTR News From Around the Web
Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.
Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to DeclineNektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Hedge Funds Aren’t Impressed By Nektar Therapeutics (NKTR)The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […] |
Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMTQ1 2020 Nektar Therapeutics Earnings Call |
Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE). |
Nektar Therapeutics to host webcast on NKTR-358 data June 5Following the virtual presentation of Phase 1b data on candidate NKTR-358 in systemic lupus erythematosus patients at EULAR 2020, Nektar Therapeutics (NKTR) will host a webcast and conference call on Friday, June 5, at 11:00 am ET to discuss the results.... |
7 Stocks Maverick Capital Continues to BuyAdobe and Avantor make the list Continue reading... |
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' JournalNektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization, in heavily pretreated patients with solid tumor cancers.1 The manuscript published today presents the safety, immune-activation and efficacy results from a Phase 1 dose-escalation study conducted in 38 patients with immunotherapy-naïve, advan... |
Oppenheimer Sticks to Their Hold Rating for Nektar TherapeuticsOppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02. |
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript | The Motley FoolNKTR earnings call for the period ending March 31, 2020. |
